Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Volumn 10, Issue 12, 2015, Pages 1670-1674

  Farago, Anna F ^a   Le, Long P ^a   Zheng, Zongli ^a   Muzikansky, Alona ^a   Drilon, Alexander ^b   Patel, Manish ^c   Bauer, Todd M ^d   Liu, Stephen V ^e   Ou, Sai Hong I ^f   Jackman, David ^g   Costa, Daniel B ^h   Multani, Pratik S ⁱ   Li, Gary G ⁱ   Hornby, Zachary ⁱ   Chow Maneval, Edna ⁱ   Luo, David ^b   Lim, Jonathan E ⁱ   Iafrate, Anthony J ^a   Shaw, Alice T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ Ignyta   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CARBOPLATIN; DOCETAXEL; ENTRECTINIB; NAVELBINE; NEUROTROPHIC TYROSINE KINASE 1; PEMBROLIZUMAB; PEMETREXED; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE A;

ADULT; ADVANCED CANCER; ARTICLE; BRAIN METASTASIS; CANCER PAIN; CANCER STAGING; CHROMOSOME REARRANGEMENT; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXON; FATIGUE; GENE FREQUENCY; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; NON SMALL CELL LUNG CANCER; PARESTHESIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; CASE REPORT; ENZYMOLOGY; FEMALE; GENE REARRANGEMENT; GENETICS; LUNG NEOPLASMS;

BENZAMIDES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I AS TOPIC; COHORT STUDIES; FEMALE; GENE REARRANGEMENT; HUMANS; INDAZOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECEPTOR, TRKA;

EID: 84948117368     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000473485.38553.f0     Document Type: Article

References (13)

1. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. Nov 2013;13(11):772-787.
2. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. Apr 2003;4(4):299-309.
3. Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drugsensitive NTRK1 rearrangements in lung cancer. Nat Med. Nov 2013;19(11):1469-1472.
4. Doebele RC, Davis LE, Vaishnavi A, et al. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov. Jul 27 2015;5(10):1049-1057.
5. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. Jan 2015;5(1):25-34.
6. Anderson D, Ciomei M, Banfi P, et al. Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101. Paper presented at: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Theapeutics2014; Barcelona, Spain.
7. Lee SJ, Li GG, Kim ST, et al. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Oncotarget. Oct 12 2015.
8. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. Dec 2014;20(12):1479-1484.
9. Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. Aug 17 2007;282(33):24131-24145.
10. Iyevleva AG, Raskin GA, Tiurin VI, et al. Novel ALK fusion partners in lung cancer. Cancer Lett. Jun 28 2015;362(1):116-121.
11. Takeuchi K, Soda M, Togashi Y, et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica. Mar 2011;96(3):464-467.
12. Tatematsu T, Sasaki H, Shimizu S, et al. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451. Mol Clin Oncol. Sep 2014;2(5):725-730.
13. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. Sep 10 2009;27(26):4247-4253.